Clinical Trial Update: A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating AK105, an anti-PD-1 therapy, in metastatic nasopharyngeal carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)

Snippet

Sponsor: Akeso | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: COMPLETED